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Second-Line Therapy for Elderly Patients with Non-small
Cell Lung Cancer Who Failed Previous Chemotherapy Is as
Effective as for Younger Patients
Chieh-Hung Wu, MD,* Wen-Chien Fan, MD,* Yuh-Min Chen, MD, PhD,*† Kun-Ta Chou, MD,*
Jen-Fu Shih, MD,*† Chun-Ming Tsai, MD,*† Yu-Chin Lee, MD,*†
and Ruery-Perng Perng, MD, PhD*
Introduction: It was found that second-line or thereafter therapies
for patients with non-small cell lung cancer (NSCLC) who failed
previous chemotherapy yielded a modest survival benefit. However,
whether elderly patients (70 years) benefit and are as suitable for
salvage therapy as nonelderly patients (70 years) are unknown.
Whether epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) is more favorable than chemotherapeutic agents as a
salvage therapy agent in elderly patients with NSCLC is also
undetermined.
Methods: We retrospectively reviewed and updated the data of our
patients with NSCLC who received second-line salvage therapies,
classified them into elderly and nonelderly groups, and compared the
efficacy, toxicities, and survival of the patients.
Results: Four hundred sixty-one cases were reviewed. The noneld-
erly group had a similar response rate, control rate, and median
survival time than the elderly group (p  0.2, p  0.9, and p  0.5,
respectively). The median progression-free time was numerically
longer in the elderly than the nonelderly patients (p  0.08). The
nonelderly group had statistically insignificantly less hematologic
toxicities than the elderly group, but more nausea and vomiting. In
addition, the use of EGFR-TKI salvage therapy, compared with
salvage chemotherapies in the elderly group, resulted in a similar
disease control rate and median survival time and more favorable
toxicity profiles.
Conclusions: There were no differences in the efficacy of salvage
chemotherapies and EGFR-TKI therapy, in terms of response rate,
control rate, and overall survival, in elderly and nonelderly patients,
and the therapies had acceptable toxicities. Age itself should not
preclude patients with NSCLC from second-line salvage therapy.
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therapy.
(J Thorac Oncol. 2010;5: 376–379)
Lung cancer is the leading cause of cancer death in theworld.1 As human longevity increases, there are more and
more elderly patients, including lung cancer patients. Lung
cancer incidence peaks at about aged 70 to 80 years, and the
mortality rate increases with age.2 The progressive decline of
organ functioning, the exhausted functional reserve, and the
higher possibility of comorbidities may result in different or
higher toxicity profiles and poor survival outcomes in elderly
patients with lung cancer, compared with younger patients,
when they receive treatment. Elderly patients are more easily
frustrated when treatment for lung cancer fails and may
refuse further salvage therapy. Thus, the treatments for el-
derly patients with lung cancer are frequently suboptimal.
With the advances in third-generation chemotherapeutic
agents, patients with advanced non-small cell lung cancer
(NSCLC) have longer disease control time and survival time,
but almost all patients with advanced NSCLC will eventually
suffer from disease progression, and die of progression or related
complications. There are several chemotherapeutic agents and
targeted agents, such as docetaxel and erlotinib, that have been
shown to effectively prolong the survival of patients with
NSCLC, compared with the best supportive care, and are con-
sidered to be effective second-line chemotherapeutic agents.3–6
Epidermal growth factor receptor-tyrosine kinase inhibi-
tors (EGFR-TKIs), such as gefitinib or erlotinib, are effective
agents used in salvage therapy for NSCLC after patients have
failed previous chemotherapy and have different toxicity profiles
compared with chemotherapeutic agents used for salvage ther-
apy.4–6 However, the majority of patients enrolled in these
clinical trials using salvage therapy against NSCLC were
younger than 70 years. Whether elderly patients are as suitable
for salvage therapy as younger patients, and whether salvage
targeted therapy is better or more tolerable than salvage chemo-
therapy in elderly patients are both unknown.
In this study, we retrospectively analyzed the data of our
nonelderly (70 years) and elderly (70 years) patients with
NSCLC who had failed previous chemotherapy and received
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salvage therapy in our clinical trials previously published in
English-language medical journals.7–15 We wanted to find out
whether there existed differences in tolerance and efficacy be-
tween young and old patients receiving salvage chemotherapy or
salvage targeted therapy with EGFR-TKI.
PATIENTS AND METHODS
We retrospectively reviewed and analyzed our pub-
lished data of patients with NSCLC who had failed previous
chemotherapy and received another chemotherapeutic regi-
men or gefitinib (an EGFR-TKI) as salvage therapy.7–15 The
data review of the patients who received salvage therapy was
approved by the institutional review board of our hospital
(VGHIRB No.: 98-03-10A). The patients were classified into
a nonelderly group (70 years) and an elderly group (70
years). The treatment response rate, time to disease progres-
sion, overall survival time, and toxicity profiles of the two
groups were compared. Treatment-related toxicities were
recorded, based on the National Cancer Institute Common
Terminology Criteria for Adverse Events version 3.16 Types
of response were assessed with the use of the Response
Evaluation Criteria in Solid Tumors.17 Response rate, time to
disease progression, and overall survival time were analyzed
with an intention-to-treat principle. Time to disease progres-
sion and overall survival time were analyzed using the
Kaplan-Meier estimation method and log-rank test. Time to
disease progression was calculated from the date of initiation
of treatment to the date of disease progression or death. If
disease progression had not occurred by the time of this
analysis, time to disease progression was considered to have
been censored at the time of the last follow-up visit. Survival
time was measured from the date of the initiation of treatment
to the date of death. Survival time was considered to have
been censored at the last follow-up time if death had not
occurred. The comparisons of clinical characteristics, re-
sponse rates, and severity of treatment-related toxicity were
performed using the 2 analysis.
RESULTS
From September 1998 to October 2005, 461 patients
with NSCLC entered nine clinical trials,7–15 which included
treatment with docetaxel alone (weekly or triweekly sched-
ules, n  185)9,11 or combined with other agents (with
ifosfamide, n  50; with gemcitabine, n  36; and with
tegafur uracil, n 24),9,13,14 gemcitabine alone (n 20) or
combined with other agents (with tegafur  uracil, n  45
and with vinorelbine, n  17),7,8,15 and gefitinib alone (n 
63) or with vinorelbine (n  21).10,12 Their data had been
reviewed and updated. Of the 461 patients, 296 (64%) were
men and 165 (36%) were women. Among them, 293 patients
(64%) were younger than 70 years, and 168 patients (36%)
were aged 70 years or older. Among the 168 patients who
were aged 70 years or older, 81 patients (48%) were aged 70
to 74 years, 61 patients (36%) were aged 75 to 79 years, 23
patients (14%) were aged 80 to 84 years, and 3 patients (2%)
were aged 85 years or older. There was no statistically
significant difference in staging and performance status be-
tween the nonelderly and elderly groups (Table 1). The
objective response rates for salvage therapy, including che-
motherapy and/or gefitinib therapy, were 24% in the noneld-
erly group and 19% in the elderly group (p  0.2). The
disease control rates were 68% in the nonelderly patient
group and 68% in the elderly patient group (p  0.9). The
median progression-free time was 4.1 months (95% confi-
dence interval [CI]: 3.6–4.6 months) in the nonelderly group
and 4.4 months (95% CI: 3.6–5.2 months) in the elderly
group (p  0.08). The median survival time was 9.3 months
(95% CI: 8.0–10.7 months) in the nonelderly group and 8.3
months (95% CI: 6.7–9.9 months) in the elderly group (p 
0.5). The 1-year survival rate was 41% in the nonelderly
group and 38% in the elderly group (Table 2). When we
further divided these patients into subgroups of salvage che-
motherapy alone (n  377) or gefitinib treatment alone (n 
63), there was still no statistical difference between the
nonelderly and elderly groups in terms of response rate,
control rate, progression-free survival, overall survival, and
1-year survival (Table 2). More importantly, the elderly
patients who received salvage chemotherapy had a response
rate, control rate, median time to disease progression, median
survival, and 1-year survival rate similar to the elderly pa-
tients who received gefitinib salvage therapy (the response
rate, control rate, median time to disease progression, median
survival, and 1-year survival rate were: 14% versus 30%, p
0.1; 66% versus 70%, p 0.8; 4.2 months versus 4.5 months,
p  0.2; 7.6 months versus 6.5 months, p  0.8; and 34%
versus 50%, p  0.8, respectively).
Severe treatment-induced hematological toxicities, in-
cluding grade 3/4 anemia (4% versus 8%, p 0.1), grade 3/4
leukopenia (19% versus 25%, p  0.1), and grade 3/4
neutropenia (25% versus 33%, p  0.09), occurred more
frequently in the elderly group. Leukopenic fever occurred at
TABLE 1. Characteristics of All Cases
N (%)
All Cases Age <70 yr Age >70 yr p
Patient no. 461 (100) 293 (64) 168 (36)
Gender 0
Male 296 (64) 156 (53) 140 (83)
Female 165 (36) 137 (47) 28 (17)
Mean age (range, yr) 63.5 (23–85) 56.7 (23–69) 75.4 (70–85)
Performance status 0.6
0 2 (0.4) 2 (0.7) 0
1 185 (40.1) 116 (39.6) 69 (41.1)
2 263 (57.0) 166 (56.7) 97 (57.7)
3 10 (2.2) 8 (2.7) 2 (1.2)
4 1 (0.2) 1 (0.3) 0
Stage 0.4
IIIb 42 (9) 29 (10) 13 (8)
IV 419 (91) 264 (90) 155 (92)
Histology 0.03
Adenocarcinoma 298 (65) 194 (66) 104 (62)
Squamous cell 72 (15) 36 (12) 36 (21)
Other NSCLC 91 (20) 63 (22) 28 (17)
NSCLC, non-small cell lung cancer.
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a slightly higher rate in the elderly group (4% versus 6%, p
0.4). With regard to nonhematologic toxicities, nausea events
were significantly more frequent in the nonelderly group
(19% versus 8%, p  0.01), but grade 3/4 fatigue was more
frequent in the elderly group (4% versus 10%, p  0.01).
When considering the patients who received salvage chemo-
therapy alone (n  377), toxicities occurred more frequently
in elderly patients with grade 3/4 anemia (5% versus 9%, p
0.1), grade 3/4 leukopenia (23% versus 30%, p  0.1), grade
3/4 neutropenia (31% versus 40%, p  0.08), leukopenic
fever (5.0% versus 7%, p  0.4), and grade 3/4 fatigue (5%
versus 12%, p  0.01). Nausea was more frequent in the
nonelderly group (23% versus 9%, p  0.008). In contrast,
when the patients who received single-agent gefitinib therapy
(n 63) were analyzed, all treatment-induced toxicities were
found to be similar between the elderly and nonelderly
groups. Furthermore, the elderly patients who received salvage
chemotherapy alone (n  139) had more frequent grade 3/4
anemia (9% versus 0%, p  0.2), grade 3/4 leukopenia (30%
versus 0%, p  0.005), grade 3/4 neutropenia (40% versus 0%,
p 0.001), leukopenic fever (7% versus 0%, p 0.4), grade 3/4
fatigue (12% versus 0%, p  0.1), nausea (9% versus 0%, p 
0.6), and vomiting (8% versus 0%, p  0.6) than the elderly
patient who received gefitinib salvage therapy.
DISCUSSION
In this study, male patients outnumbered female pa-
tients in the elderly group (M/F ratio 5), whereas they were
relatively equal in the nonelderly group (M/F ratio  1.1).
The reason for the male predominance in the elderly group is
that these were patients in a veterans’ hospital. Adenocarci-
noma was the main histologic subtype, and squamous cell
carcinoma was relatively more common in the elderly group
(nonelderly versus elderly: 12% versus 21%); these results
were consistent with our previous study of NSCLC in very
young and very old patients.18
Another of our previous studies showed that among
chemo-naive patients with NSCLC who received first-line
chemotherapy, elderly patients had response rates and sur-
vival comparable with nonelderly patients.19 The Ederly
Lung Cancer Vinorelbine Italian Study also showed that
elderly patients that received first-line chemotherapy had
better survival and symptom control than those who received
supportive care only.20 Recently, Crino` et al.21 reported a
randomized phase II study comparing single agent vinorel-
bine versus gefitinib in chemo-naive elderly NSCLC and the
results showed at least in certain patients that EGFR-TKI may
produce outcomes similar to single agent chemotherapy in
Caucasians, even though the primary end point of superior
progression-free survival for gefitinib was not met in this
study. However, there is currently no study comparing sur-
vival and toxicities with second-line therapy in elderly and
nonelderly patients with NSCLC. In this study, there were
similar response rates and control rates in the elderly patients
and the nonelderly patients. There was no statistically signif-
icant difference between the two groups in progression-free
time, overall survival time, and 1-year survival rate (Figures
1 and 2). Furthermore, in the subgroup analysis, both salvage
FIGURE 1. Time to disease progression of 293 nonelderly
(70 years) cases and 168 elderly (70 years) cases who
received salvage chemotherapy or gefitinib salvage therapy.
The median time to disease progression were 4.1 months
and 4.4 months, respectively (p  0.8).
TABLE 2. Response Rate, Control Rate, and Survival in All Cases, in the Salvage Chemotherapy Group, and in the Gefitinib
Salvage Therapy Group
All Cases Salvage Chemotherapy Group Gefitinib Salvage Group
Age <70 yr Age >70 yr p Age <70 yr Age >70 yr p Age <70 yr Age >70 yr p
Patient no. (%) 293 (64) 168 (36) 238 (63) 139 (37) 43 (68) 20 (32)
Chemotherapy cycle, mean  SD Nil Nil Nil 3.9  1.9 3.6  1.8 0.4 Nil Nil Nil
Response rate, % 24 19 0.2 18 14 0.4 49 30 0.2
Control rate, % 68 68 0.9 66 66 0.9 77 70 0.6
Median time to disease progression,
mo (95% CI)
4.1 (3.6–4.6) 4.4 (3.6–5.2) 0.08 3.7 (3.1–4.3) 4.2 (3.4–4.9) 0.1 7.5 (3.7–11.3) 4.5 (0–11.7) 0.8
Median survival, mo (95% CI) 9.3 (8.0–10.7) 8.3 (6.7–9.9) 0.5 8.4 (7.0–9.8) 7.6 (6.2–9.0) 0.5 11.0 (5.7–16.2) 9.9 (0–22.1) 0.6
1-yr survival rate, % 41 38 38 34 46 50
CI, confidence interval.
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chemotherapy and salvage EGFR-TKI therapy showed sim-
ilar response and survival rates in both age groups. In addi-
tion, compared with salvage chemotherapy, salvage EGFR-
TKI therapy in the elderly group resulted in similar response
rates and 1-year survival rate (chemotherapy versus EGFR-
TKI: 34% versus 50%, p  0.8) and had more favorable
toxicity profiles. It can be said that old age should not be the
factor precluding patients with NSCLC from chemotherapy
or EGFR-TKI therapy.
With regard to treatment-related toxicities, both groups
had similar hematologic toxicities, but there were more
events of fatigue in the elderly patient group and more nausea
events in the nonelderly group. Furthermore, in the subgroup
analysis, elderly patients who were given salvage chemother-
apy had more hematologic toxicities, especially leukopenia
and neutropenia, than those who received EGFR-TKI therapy,
although leukopenic fever and death due to leukopenic fever
were minor and were not statistically significant between the 2
therapies. The elderly patients who underwent salvage chemo-
therapy had more nausea and fatigue as a result, and those who
received EGFR-TKI salvage therapy had more skin rash events.
It can be said that salvage chemotherapy and EGFR-TKI therapy
result in similar survival in elderly patients with NSCLC, and
that EGFR-TKI therapy has more favorable toxicity profiles.
This may explain why EGFR-TKI therapy tends to have a
numerical longer 1-year survival rate than salvage chemotherapy
(chemotherapy versus EGFR-TKI: 34% versus 50%, p 0.8) in
elderly patients with NSCLC.
In conclusion, the survival time and hematological
toxicities of elderly patients who meet the stringent eligibility
for our clinical trials and who received second-line therapy
for NSCLC, including both salvage chemotherapy and sal-
vage EGFR-TKI, were comparable with those of nonelderly
patients. Thus, age itself should not preclude patients from
undergoing second-line therapy for NSCLC. Furthermore,
EGFR-TKI therapy had similar response rates and survival
time, and more favorable toxicity profiles compared with
salvage chemotherapy in elderly patients with NSCLC.
REFERENCES
1. Schottenfeld D. Etiology and epidemiology of lung cancer. In HI Pass,
JB Mitchell, DH Johnson, et al. Lung Cancer: Principles and Practice.
Philadelphia, PA: Lippincott Williams & Wilkins, 2000. Pp. 367–388.
2. Lee-Chiong TL Jr, Matthay RA. Lung cancer in the elderly patient. Clin
Chest Med 1993;14:453–478.
3. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial
of docetaxel versus best supportive care in patients with non-small-cell
lung cancer previously treated with platinum-based chemotherapy.
J Clin Oncol 2000;18:2085–2103.
4. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously
treated non-small cell lung cancer. N Engl J Med 2005;353:123–132.
5. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15–32,
of gefitinib versus docetaxel in previously treated Japanese patients with
non-small-cell lung cancer. J Clin Oncol 2008;26:4233–4235.
6. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously
treated non-small-cell lung cancer (INTEREST): a randomised phase III
trial. Lancet 2008;372:1809–1818.
7. Chen YM, Perng RP, Tsai CM, et al. A phase II trial of gemcitabine plus
UFUR combination chemotherapy in non-small-cell lung cancer patients
failing previous chemotherapy. Lung Cancer 2006;52:333–338.
8. Chen YM, Tsai CM, Perng RP. Clinical experience with single-agent
gemcitabine chemotherapy in patients with non-small-cell lung cancer in
whom previous chemotherapy has failed. J ChinMed Assoc 2005;68:163–166.
9. Chou KT, Chen YM, Shih JF, et al. Phase II randomized study of weekly
docetaxel alone or plus UFUR treatment in non-small cell lung cancer
patients who failed previous chemotherapy. Lung Cancer 2008;59:64–68.
10. Chen YM, Perng RP, Tsai CM. Gefitinib treatment is highly effective in
non-small-cell lung cancer patients failing previous chemotherapy in
Taiwan: a prospective phase II study. J Chemother 2005;17:679–684.
11. Chen YM, Shih JF, Perng RP, et al. A randomized trial of different
docetaxel schedules in non-small cell lung cancer patients who failed
previous platinum-based chemotherapy. Chest 2006;129:1031–1038.
12. Chen YM, Liu JM, Chou TY, et al. Phase II randomized study of daily
gefitinib treatment alone or with vinorelbine every 2 weeks in patients
with adenocarcinoma of the lung who failed at least 2 regimens of
chemotherapy. Cancer 2007;109:1821–1828.
13. Chen YM, Perng RP, Lin WC, et al. Phase II study of docetaxel and
gemcitabine combination chemotherapy in non-small-cell lung cancer pa-
tients failing previous chemotherapy. Am J Clin Oncol 2002;25:509–512.
14. Chen YM, Shih JF, Lee CS, et al. Phase II study of docetaxel and
ifosfamide combination chemotherapy in non-small-cell lung cancer
patients failing previous chemotherapy with or without paclitaxel. Lung
Cancer 2003;39:209–214.
15. Chen YM, Perng RP, Lee CS, et al. Phase II study of gemcitabine and
vinorelbine combination chemotherapy in patients with non-small-cell
lung cancer not responding to previous chemotherapy. Am J Clin Oncol
2003;26:567–570.
16. Common Terminology Criteria for Adverse Events (CTCAE) v3.0
(NCI/CTEP web site). Available at: https:webapps.ctep.nci.nih.gov/
webobjs/ctc/webhelp/welcome_to_ctcae.htm. Accessed July 15, 2009.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation
criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J
Cancer 2009;45:228–247.
18. Kuo C-W, Chen Y-M, Chao J-Y, et al. Non-small cell lung cancer in
very young and very old patients. Chest 2000;117:354–357.
19. Chen YM, Perng RP, Shih JF, et al. Chemotherapy for non-small cell
lung cancer in elderly patients. Chest 2005;128:132–139.
20. Effects of vinorelbine on quality of life and survival of elderly patients
with advanced non-small-cell lung cancer. The Elderly Lung Cancer
Vinorelbine Italian Study Group. J Natl Cancer Inst 1999;91:66–72.
21. Crino` L, Cappuzzo F, Zatloukal P, et al. Gefitnib versus vinorelbine in
chemotherapy-naïve elderly patients with advanced non-small-cell lung
cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008;26:
4253–4260.
FIGURE 2. Overall survival of 293 nonelderly (70 years)
cases and 168 elderly (70 years) cases who received salvage
chemotherapy or gefitinib salvage therapy. The median overall
survival were 9.3 and 8.3 months, respectively (p  0.5).
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